Congress Urged Not to Slash Cancer Research Funding in 'Fiscal Cliff' Negotiations

Share this article:
(ChemotherapyAdvisor) – The Lung Cancer Alliance (LCA), a patient-advocacy organization, is urging Congress to “hold cancer research harmless from the fiscal cliff” during upcoming budget negotiations.

With Congress and the White House looking for ways to curtail the growth of federal spending, it is important to view cancer research budgets as “not a luxury but a necessity,” said LCA President and CEO Laurie Fenton-Ambrose.

"The incidence rate of cancer is higher now than it was 40 years ago and it is the leading cause of death in adults under the age of 75," Fenton-Ambrose said. "With the number of patients and the cost of treatment escalating, we cannot afford to short-change the agencies of government involved in cancer research and the review of new and more targeted cancer drugs now."

More funding needs to be devoted to cancers associated with high mortality rates, she argued – including lung and pancreatic cancers, which represent an estimated 33% of cancer deaths in the United States but research for which is less well-funded than other types of cancer.

She also called for a comprehensive action plan to guide public funding decisions for cancer research, and a system of benchmarks with which research outcomes can be assessed.

"This is the taxpayers' money we are investing in cancer research and treatment development and there has to be more accountability," she said.

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Lung Cancer

Tumor Promoter Expression May Aid in Lung Cancer Diagnosis

Tumor Promoter Expression May Aid in Lung Cancer ...

Cav-1 and SW-CNT could prove useful for the diagnosis and prognosis of lung cancer.

Novel TAZ-targeted Therapy to Fight Against Non-Small Cell Lung Cancer

Novel TAZ-targeted Therapy to Fight Against Non-Small Cell ...

High transcriptional coactivator with PDZ-binding motif levels may be markers of poor prognosis non-small cell lung cancer.

AZD3965 May Be New Treatment Option for Small Cell Lung Cancer

AZD3965 May Be New Treatment Option for Small ...

Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.